

This statement has been reviewed and remains in place. This is due to the ongoing fragile status of ADHD medicine supplies. This will be reassessed and reviewed by 1st February 2025, or before should circumstances change.

**Medicines Management Team
Pharmacy & Medicines Directorate
3rd October 2024**

**Attention Deficit Hyperactivity Disorder (ADHD) Medicines Shortage –
Requests for NHS Treatment of New Adult Patients Following Private
Diagnosis – Review Version 3**

There continues to be intermittent supply issues affecting a range of ADHD medicines, strengths and formulations.

It is essential that the available resources (medication and monitoring) are utilised to manage active patients currently prescribed these medicines, or those NHS patients that have been deferred treatment initiation to date.

Discussions are currently ongoing between Specialist services and Primary Care regarding the NHS Grampian position and treatment pathway for referral, treatment and monitoring of adult patients with ADHD.

Due to these factors NHS Grampian cannot currently support the initiation of treatment for NEW adult patients who have been referred following a Private diagnosis, or continuation of treatment undertaken privately.

Any patient requesting new NHS initiation of ADHD treatments following a Private diagnosis, or continuation of treatment undertaken privately, should be advised that this is not currently possible.

This position will be reviewed either when the treatment pathway has been agreed or by the 1st February 2025, whichever is earliest.

Medicines Management Team
Pharmacy & Medicines Directorate
Gram.medicinesmanagement@nhs.scot
1st October 2024